E7389
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Soft Tissue Sarcoma
Conditions
Soft Tissue Sarcoma
Trial Timeline
Jan 1, 2007 → Feb 1, 2013
NCT ID
NCT00413192About E7389
E7389 is a phase 2 stage product being developed by Eisai for Soft Tissue Sarcoma. The current trial status is completed. This product is registered under clinical trial identifier NCT00413192. Target conditions include Soft Tissue Sarcoma.
What happened to similar drugs?
2 of 15 similar drugs in Soft Tissue Sarcoma were approved
Approved (2) Terminated (3) Active (11)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (8)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01432886 | Phase 1 | Completed |
| NCT00413192 | Phase 2 | Completed |
| NCT00326950 | Phase 1 | Completed |
| NCT00278993 | Phase 2 | Completed |
| NCT00246090 | Phase 2 | Completed |
| NCT00097721 | Phase 2 | Completed |
| NCT00069264 | Phase 1 | Completed |
| NCT00069277 | Phase 1 | Completed |
Competing Products
20 competing products in Soft Tissue Sarcoma